Positive Aspects of Transcervical Fibroid Ablation, Strong Clinical Results, Provides Facilities with Confidence in Treating Fibroids and Minimizing Potential Viral Risks – Procedural Volumes Increasing Redwood City, CA – June 22, 2020 - Gynesonics®, a women’s healthcare company focused on the
Gynesonics Announces Publications on Healthcare Economic Analyses Demonstrating Cost Savings
The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy. Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the development of
Gynesonics Receives FDA Clearance to Market Next Generation Sonata System 2.1
EARLY LAUNCH IN EUROPE CONTRIBUTES TO SIGNIFICANT PROCEDURAL GROWTH Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the
Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress
2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine
Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and Market Access
Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive
Gynesonics Announces Five-Year Patient Outcomes with the Sonata System Published in Journal of Gynecologic Surgery
VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas)
Interview with Stamford Health System Chief of Gynecology
Dr. Scott Chudnoff, Chief of Gynecology at Stamford Health System in Stamford, Connecticut, is the lead author of the SONATA Trial 12 month results published in the January 2019 issue of Obstetrics and Gynecology.
Gynesonics Announces Publication of Final SONATA IDE Pivotal Trial Results in the Journal, Obstetrics And Gynecology
Robust Outcomes Support the Potential of the Sonata System as a First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as